Animal study · Supplements / medicine · 2 Sept 2026
Late-life semaglutide treatment slows ageing and extends lifespan in female mice
Source: Nature
What the research found
Study (mice). Feng, Barthez, Chen and colleagues treated 20-month-old female C57BL/6 mice with the GLP-1 receptor agonist semaglutide. Median lifespan was 834 days versus 742 in controls (about 12% longer). Three months of treatment improved function and dampened aging hallmarks; treated mice ate about 24% fewer calories. A calorie-matched comparison suggested extra gains in exploratory drive, spatial memory, and glucose control beyond restriction alone. This is laboratory animal work in one sex and strain, not a human longevity trial. Semaglutide remains a prescription medicine for approved uses. Off-label aging use is clinician-only. This is not medical advice and not a reason to start, stop, or replace any drug.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34